SWTX — SpringWorks Therapeutics Share News
0.000.00%
Last trade - 00:00- $3.54bn
- $3.25bn
- $191.59m
SpringWorks gains after FDA approves non-cancerous tumors treatment for adults
SpringWorks rises after FDA approves drug treating non-cancerous tumors in adults
US FDA approves SpringWorks Therapeutics' non-cancerous tumor treatment (updated)
US FDA approves SpringWorks Therapeutics' non-cancerous tumor treatment
U.S. RESEARCH ROUNDUP-Clorox, GoDaddy, Reynolds Consumer Products
SpringWorks climbs as genetic disorder treatment succeeds in trial
Brief: Springworks Therapeutics Announces Positive Topline Results From The Phase 2B Reneu Trial Of Mirdametinib In Nf1-Pn
SpringWorks Therapeutics Inc reports results for the quarter ended in September - Earnings Summary
SpringWorks Therapeutics Inc expected to post a loss of $1.33 a share - Earnings Preview
SpringWorks Therapeutics Inc reports results for the quarter ended in June - Earnings Summary
Brief: SpringWorks Therapeutics posts Q2 basic EPS USD -1.25
SpringWorks Therapeutics Inc expected to post a loss of $1.26 a share - Earnings Preview
Brief: Springworks Therapeutics Announces PDUFA Date Extension For Nirogacestat NDA
US FDA delays decision on SpringWorks Therapeutics' tumor treatment (updated)
US FDA delays decision on SpringWorks Therapeutics' tumor treatment
Brief: Springworks Therapeutics Completes Enrollment Of Mid-stage Study For Ovarian Tumor Drug
Brief: SpringWorks Announces Presentation Of More Data From Phase 3 DeFi Trial Of Nirogacestat
Live Markets: Digimarc among top 'squeeze' targets -S3 Partners
SpringWorks Therapeutics Inc reports results for the quarter ended in March - Earnings Summary